Drug intelligence / Profile preview

probiotic gel

Development stage: Phase 4
Lead developer: Cairo University
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

Probiotic gel is a novel topical live biotherapeutic product (LBP) formulation developed for the treatment of minor recurrent aphthous ulcers (RAU). Developed by researchers at Cairo University, this gel contains beneficial microorganisms designed to be applied directly to oral mucosal lesions. The mechanism of action involves modulating the local oral microbiome and reducing inflammation, potentially by suppressing pro-inflammatory cytokines and promoting tissue repair. In clinical evaluations, it is being compared against the standard-of-care corticosteroid triamcinolone acetonide, with salivary microRNA-146a serving as a biological marker to track the resolution of inflammation and healing progress.

Other names: topical probiotic gel

Beyond the preview

Go deeper on probiotic gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on probiotic gel.

Explore the full profile